Occupational exposure to specific industrial solvents increases the odds of developing Parkinson’s disease, with risks climbing as workers encounter a greater number of chemical types. A cross-sectional study published in Scientific Reports links seven distinct workplace solvents to higher neurodegenerative disease odds among thousands of participants.
Industrial Chemicals Linked to Disease
Researchers evaluated data from 41,315 participants in the Parkinson’s Progression Markers Initiative (PPMI) Online study to investigate whether workplace chemical exposures help explain the origins of Parkinson’s disease, News-Medical reported. The investigation focused on self-reported workplace use of 13 solvent categories for at least 100 days over a lifetime.
When evaluating all 13 solvents simultaneously, positive associations persisted for kerosene, trichloroethylene (TCE), mineral spirits, and carbon tetrachloride. Participants reporting exposure to kerosene faced 50% higher odds of Parkinson’s disease, while those exposed to TCE experienced 65% higher odds. Mineral spirits and carbon tetrachloride showed 27% and 28% higher odds, respectively.
Cumulative Exposure and Risk Factors
The study identified a clear exposure-response trend. Each additional distinct solvent reported by a participant was associated with approximately 16% higher odds of the neurodegenerative condition. Participants reporting exposure to three or more solvents had 52% higher odds compared to unexposed individuals.
| Solvent Type | Adjusted Odds Ratio | Statistical Significance |
|---|---|---|
| Kerosene | 1.50 to 1.74 | P < .001 |
| Trichloroethylene (TCE) | 1.71 | P < .001 |
| Carbon Tetrachloride | 1.28 to 1.69 | P < .001 |
| Mineral Spirits | 1.27 to 1.42 | P < .001 |
Study Limitations and Future Research
The authors of the Scientific Reports study noted several limitations, including reliance on retrospective self-reported questionnaires and a lack of age data for control participants. Furthermore, about 26% of participants with Parkinson’s disease were unsure which solvents they had used, which could introduce recall bias.
Luna-Rangel encouraged workers to use personal protective equipment and advised clinicians to ask about lifetime occupational exposures while monitoring patients for potential neurologic symptoms, according to Medscape.
The Parkinson’s Progression Markers Initiative (PPMI) was launched in 2010 by The Michael J. Fox Foundation in collaboration with dozens of public and private partners to address the lack of reliable ways to track disease progression.
The study follows people with Parkinson’s, people at risk, and people without the disease at 50-plus medical centers worldwide, creating an open-access data resource that has been downloaded over 40 million times and cited in more than 400 scientific publications.
PPMI has grown into the largest and most comprehensive Parkinson’s study of its kind, building an unparalleled collection of clinical, imaging, and biospecimen data from over 4,000 volunteers who completed in-person visits.
More than 46,000 participants have shared information online, and nearly 100,000 have completed smell tests through its remote screening system. One of its most significant contributions is the validation of the alpha-synuclein seed amplification assay, a biomarker for Parkinson’s disease.